Abbvie Inc Inventory Turnover Ratio (COS)

Cost of Sales Formula, Quarterly Results, Trends, Rankings, Statistics

Due to inventory build up in the first quarter 2026, Abbvie Inc 's inventory turnover ratio sequentially decreased to 3.7 in the first quarter 2026, unsurprisingly, as the Abbvie Inc markets continue to deteriorate, and ABBV's faces growing challenges to bring down its inventories. Abbvie Inc 's average inventory processing period in the Mar 31 2026 quarter, has increased to 99 days, from 97 days, in the Dec 31 2025 quarter.

Within Healthcare sector 105 other companies have achieved higher inventory turnover ratio. While in terms of ranking among all other companies, the company has moved form 666 in the fourth quarter 2025, to 745.

ABBV Inventory Turnover Ratio using Sales Formula
What is Inventory Turnover Ratio?
What is Abbvie Inc Market Share?

What is Inventory Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Inventory Turnover▼

None ▼

Inventory Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ABBV Inventory Turnover Ratio	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Inventory Growth	11.56 %	18.42 %	10.97 %	17.59 %	6.62 %
Y / Y Cost of Sales Growth	5.4 %	3.55 %	25.93 %	3.43 %	-2.25 %
Inventory Turnover Ratio (TTM)	3.7	3.76	3.88	3.74	3.87
ABBV's Total Ranking	# 745	# 666	# 348	# 798	# 599
Average inventory processing period	99	97	94	97	94
Seq. Inventory Growth	1.98 %	0.26 %	-0.44 %	9.59 %	8.25 %
Seq. Cost of Sales Growth	-7.34 %	-14.18 %	22.04 %	8.6 %	-8.96 %

Inventory Turnover Ratio Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 22
Healthcare Sector	# 106
Overall Market	# 745

Inventory Turnover Ratio Statistics
High	Average	Low
6.71	4.18	2.08
(Sep. 30, 2013)		(Sep. 30, 2012)

ABBV Company Profile >> Back to ABBV Efficiency Comparisons >> Compare ABBV Inventory Turnover Ratio to its Competitors

Financial Statements
Abbvie Inc 's Inventories	$ 5,049 Millions	Visit ABBV's Balance sheet
Abbvie Inc 's Cost of Revenues TTM	$ 18,420 Millions	Visit ABBV's Income Statement
What are ABBV's Sales?		Visit ABBV's Sales by Segment

Other Inventory Turnover Ratios
Abbvie Inc 's Inventory to Sales Ratio
U.S. Durable Goods Inventory to Shipment Ratio By Product
Major Pharmaceutical Preparations Industry Inventory Turnover Trends and Statistics
Healthcare Sector Inventory Turnover Statistics
Inventory Turnover Trends for overall market
ABBV's Inventory Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Inventory Turnover
Lowest Ranking Inventory Turnover
Inventory Turnover for ABBV's Competitors
Inventory Turnover Ratio for ABBV's Suppliers
Inventory Turnover Ratio for ABBV's Customers

You may also want to know
ABBV's Sales Growth Rates	ABBV's Pe Price to earnings ratio	ABBV's Receivables Turnover Ratio	ABBV's Stock Quote
ABBV's Net Income Growth Rates	ABBV's Ps Price to Sales ratio	ABBV's Sales per Employee	ABBV's Asset Turnover Ratio
ABBV's Net Margin	ABBV's Pb Price to Book ratio	ABBV's Financial Strength Ratios	ABBV's Dividend Payout Ratio

Companies with similar Inventory Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector	Inventory Turnover Ratio	Cost of revenues at quarter ending Mar 31 2026	Inventories at quarter ending Mar 31 2026
Lantheus Holdings Inc	9.75	$ 610.000 Millions	$ 63 Millions
Sotera Health Company	9.58	$ 531.000 Millions	$ 55 Millions
Warby Parker Inc	9.23	$ 415.000 Millions	$ 45 Millions
Tarsus Pharmaceuticals Inc	9.09	$ 37.864 Millions	$ 4 Millions
National Vision Holdings Inc	8.90	$ 833.415 Millions	$ 94 Millions
Myriad Genetics Inc	8.35	$ 248.000 Millions	$ 30 Millions
Pulse Biosciences Inc	8.08	$ 0.909 Millions	$ 0 Millions
Castle Biosciences Inc	7.97	$ 75.178 Millions	$ 9 Millions
Moderna Inc	7.96	$ 1,733.000 Millions	$ 218 Millions
Carlsmed Inc	7.95	$ 12.557 Millions	$ 2 Millions
Inogen Inc	7.80	$ 195.741 Millions	$ 25 Millions
Cardiff Lexington Corporation	7.70	$ 4.159 Millions	$ 1 Millions
Novavax inc	7.67	$ 89.620 Millions	$ 12 Millions
Prophase Labs Inc	7.64	$ 2.361 Millions	$ 0 Millions
Bellevue Life Sciences Acquisition Corp	7.62	$ 1.986 Millions	$ 0 Millions
Lifemd Inc	7.60	$ 24.000 Millions	$ 3 Millions
Charles River Laboratories International inc	7.56	$ 2,346.239 Millions	$ 310 Millions
Adaptive Biotechnologies Corporation	7.43	$ 73.088 Millions	$ 10 Millions
Puma Biotechnology Inc	7.19	$ 58.025 Millions	$ 8 Millions
Fonar Corporation	7.06	$ 19.685 Millions	$ 3 Millions
Carlisle Companies Incorporated	6.71	$ 3,206.100 Millions	$ 478 Millions
Hims and Hers Health Inc	6.58	$ 670.000 Millions	$ 102 Millions
Vanda Pharmaceuticals Inc	6.54	$ 12.682 Millions	$ 2 Millions
Twist Bioscience Corporation	6.50	$ 196.251 Millions	$ 30 Millions
Phathom Pharmaceuticals Inc	6.48	$ 30.871 Millions	$ 5 Millions
Precision Optics Corporation Inc	6.47	$ 24.932 Millions	$ 4 Millions
Nuo Therapeutics Inc	6.42	$ 1.331 Millions	$ 0 Millions
Collegium Pharmaceutical Inc	6.41	$ 256.071 Millions	$ 40 Millions
Veracyte Inc	6.05	$ 132.000 Millions	$ 22 Millions
Kewaunee Scientific Corporation	5.98	$ 200.155 Millions	$ 33 Millions

Date modified: 2026-09-08T15:18:59+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.